Published in Jpn J Cancer Res on September 01, 1986
Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol (2013) 1.06
Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel. J Ovarian Res (2012) 0.81
BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells. Biomark Insights (2007) 0.77
A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry (1978) 25.54
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A (1987) 7.38
Cornell Scale for Depression in Dementia. Biol Psychiatry (1988) 6.61
'Vascular depression' hypothesis. Arch Gen Psychiatry (1997) 6.59
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A (1992) 5.24
Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res (1985) 5.09
Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol (1986) 4.75
Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A (2000) 4.55
Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res (1981) 4.30
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene (1999) 3.32
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A (1999) 3.26
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22
Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (1977) 3.11
Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci U S A (1986) 2.99
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol (1974) 2.89
Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res (1982) 2.82
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res (1987) 2.67
Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol (1973) 2.61
Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med (1978) 2.36
Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res (1988) 2.35
Fungemia with compromised host resistance. A study of 70 cases. Ann Intern Med (1974) 2.25
Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (1984) 2.24
Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med (1977) 2.20
Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst (1996) 2.17
In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients. Eur J Nucl Med (1997) 2.15
Maintenance of granuloma formation in pulmonary sarcoidosis by T lymphocytes within the lung. N Engl J Med (1980) 2.07
Clinically defined vascular depression. Am J Psychiatry (1997) 2.06
Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO J (2000) 2.05
De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer (2009) 2.05
Staging laparotomy in early ovarian cancer. JAMA (1983) 2.02
The anthracycline antineoplastic drugs. N Engl J Med (1981) 2.02
TB testing. Vet Rec (1996) 2.01
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Invasive aspergillosis. Absence of detectable antibody response. Am Rev Respir Dis (1971) 1.96
The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry (1993) 1.92
Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem (1989) 1.89
Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol (1985) 1.86
Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res (1989) 1.85
Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance. 170- to 180-kilodalton membrane glycoprotein is an ATPase. J Biol Chem (1988) 1.85
Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res (1983) 1.84
Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst (1992) 1.82
Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood (1992) 1.80
BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. J Cardiovasc Pharmacol (1986) 1.79
Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry (2000) 1.78
Management of infections in patients with leukemia and lymphoma: current concepts and experimental approaches. Semin Hematol (1972) 1.78
Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature (1973) 1.78
Chemotherapy of ovarian cancer. Semin Oncol (1984) 1.75
Localization of the immune response in sarcoidosis. Am Rev Respir Dis (1979) 1.74
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer. J Clin Oncol (1992) 1.74
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A (1987) 1.71
ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene (1999) 1.70
Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res (1986) 1.68
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol (1995) 1.67
Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med (1982) 1.67
Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer (1975) 1.66
A DNA-topoisomerase-II-binding protein with eight repeating regions similar to DNA-repair enzymes and to a cell-cycle regulator. Eur J Biochem (1997) 1.65
Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res (1984) 1.64
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res (1998) 1.61
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61
Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med (1983) 1.58
Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene (1999) 1.58
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol (2000) 1.58
A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun (1999) 1.56
Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res (1988) 1.55
Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol (1986) 1.55
Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res (1979) 1.55
Treatment of recurrent ovarian cancer: increasing options--"recurrent" results. J Clin Oncol (1997) 1.55
Disability in geriatric depression. Am J Psychiatry (1996) 1.55
G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells. Oncogene (2006) 1.53
Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene (2001) 1.53
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol (1991) 1.53
Inhibition by glibenclamide of the vasorelaxant action of cromakalim in the rat. Br J Pharmacol (1989) 1.52
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52